当前位置: 首页 >> 检索结果
261. Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.
作者: Milton Packer.;Javed Butler.;Cordula Zeller.;Stuart J Pocock.;Martina Brueckmann.;João Pedro Ferreira.;Gerasimos Filippatos.;Muhammad Shariq Usman.;Faiez Zannad.;Stefan D Anker.
来源: Circulation. 2023年148卷13期1011-1022页
It is not known whether the benefits of sodium-glucose cotransporter 2 inhibitors in heart failure persist after years of therapy.
262. Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial.
作者: Frederik M Zimmermann.;Victoria Y Ding.;Nico H J Pijls.;Zsolt Piroth.;Albert H M van Straten.;Laszlo Szekely.;Giedrius Davidavicius.;Gintaras Kalinauskas.;Samer Mansour.;Rajesh Kharbanda.;Nikolaos Östlund-Papadogeorgos.;Adel Aminian.;Keith G Oldroyd.;Nawwar Al-Attar.;Nikola Jagic.;Jan-Henk E Dambrink.;Petr Kala.;Oskar Angeras.;Philip MacCarthy.;Olaf Wendler.;Filip Casselman.;Nils Witt.;Kreton Mavromatis.;Steven E S Miner.;Jaydeep Sarma.;Thomas Engstrøm.;Evald H Christiansen.;Pim A L Tonino.;Michael J Reardon.;Hisao Otsuki.;Yuhei Kobayashi.;Mark A Hlatky.;Kenneth W Mahaffey.;Manisha Desai.;Y Joseph Woo.;Alan C Yeung.;Bernard De Bruyne.;William F Fearon.; .
来源: Circulation. 2023年148卷12期950-958页
Previous studies comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients with multivessel coronary disease not involving the left main have shown significantly lower rates of death, myocardial infarction (MI), or stroke after CABG. These studies did not routinely use current-generation drug-eluting stents or fractional flow reserve (FFR) to guide PCI.
263. Arrhythmia and Death Following Percutaneous Revascularization in Ischemic Left Ventricular Dysfunction: Prespecified Analyses From the REVIVED-BCIS2 Trial.
作者: Divaka Perera.;Holly P Morgan.;Matthew Ryan.;Matthew Dodd.;Tim Clayton.;Peter D O'Kane.;John P Greenwood.;Simon J Walsh.;Roshan Weerackody.;Adam McDiarmid.;George Amin-Youssef.;Julian Strange.;Bhavik Modi.;Timothy Lockie.;Kai Hogrefe.;Fozia Z Ahmed.;Miles Behan.;Nicholas Jenkins.;Eltigani Abdelaal.;Michelle Anderson.;Stuart Watkins.;Richard Evans.;Christopher A Rinaldi.;Mark C Petrie.; .
来源: Circulation. 2023年148卷11期862-871页
Ventricular arrhythmia is an important cause of mortality in patients with ischemic left ventricular dysfunction. Revascularization with coronary artery bypass graft or percutaneous coronary intervention is often recommended for these patients before implantation of a cardiac defibrillator because it is assumed that this may reduce the incidence of fatal and potentially fatal ventricular arrhythmias, although this premise has not been evaluated in a randomized trial to date.
264. Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial.
作者: Barry A Borlaug.;Yogesh N V Reddy.;Amanda Braun.;Hidemi Sorimachi.;Massar Omar.;Dejana Popovic.;Alessio Alogna.;Michael D Jensen.;Rickey Carter.
来源: Circulation. 2023年148卷10期834-844页
Sodium-glucose cotransporter-2 inhibitors reduce risk of hospitalization for heart failure in patients who have heart failure with preserved ejection fraction (HFpEF), but the hemodynamic mechanisms underlying these benefits remain unclear. This study sought to determine whether treatment with dapagliflozin affects pulmonary capillary wedge pressure (PCWP) at rest and during exercise in patients with HFpEF.
265. EXACT Trial: Results of the Phase 1 Dose-Escalation Study.
作者: Thomas J Povsic.;Timothy D Henry.;Jay H Traverse.;R David Anderson.;Geoffrey A Answini.;Benjamin C Sun.;George J Arnaoutakis.;Konstantinos D Boudoulas.;Adam R Williams.;Howard C Dittrich.;Elizabeth A Tarka.;David A Latter.;E Magnus Ohman.;Mark W Peterson.;Dawn Byrnes.;Carl J Pepine.;Marcelo F DiCarli.;Ronald G Crystal.;Todd K Rosengart.;Nahush A Mokadam.
来源: Circ Cardiovasc Interv. 2023年16卷8期e012997页
New therapies are needed for patients with refractory angina. Encoberminogene rezmadenovec (XC001), a novel adenoviral-5 vector coding for all 3 major isoforms of VEGF (vascular endothelial growth factor), demonstrated enhanced local angiogenesis in preclinical models; however, the maximal tolerated dose and safety of direct epicardial administration remain unknown.
266. DASH-HF Study: A Pragmatic Quality Improvement Randomized Implementation Trial for Patients With Heart Failure With Reduced Ejection Fraction.
作者: Aradhana Verma.;Gregg C Fonarow.;Jeffrey J Hsu.;Cynthia A Jackevicius.;Freny Vaghaiwalla Mody.;Amanda Nguyen.;Omid Amidi.;Sarah Goldberg.;Reeta Vetrivel.;Deepti Upparapalli.;Kleanthis Theodoropoulos.;Stephanie Gregorio.;Donald S Chang.;Kristina Bostrom.;Andrew D Althouse.;Boback Ziaeian.
来源: Circ Heart Fail. 2023年16卷9期e010278页
Heart failure is a prevailing diagnosis of hospitalization and readmission within 6 months, and nearly a quarter of these patients die within a year. Guideline-directed medication therapies reduce risk of mortality by 73% over 2 years; however, the implementation of these therapies to their target dose in clinical practice continues to be challenging. In 2020, the Veterans Affairs (VA) Health Care System developed a HF dashboard to monitor and improve outpatient HF management. The DASH-HF (Dashboard Activated Services and Telehealth for Heart Failure) study is a randomized, pragmatic clinical trial to evaluate proactive dashboard-directed telehealth clinics to improve the use and dosing of guideline-directed medication therapy for patients with heart failure with reduced ejection fraction not on optimal guideline-directed medication therapy within the VA.
267. STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial.
作者: Frans Van de Werf.;Arsen D Ristić.;Oleg V Averkov.;Alexandra Arias-Mendoza.;Yves Lambert.;José F Kerr Saraiva.;Pablo Sepulveda.;Fernando Rosell-Ortiz.;John K French.;Ljilja B Musić.;Katleen Vandenberghe.;Kris Bogaerts.;Cynthia M Westerhout.;Alain Pagès.;Thierry Danays.;Kevin R Bainey.;Peter Sinnaeve.;Patrick Goldstein.;Robert C Welsh.;Paul W Armstrong.; .
来源: Circulation. 2023年148卷9期753-764页
ST-segment-elevation myocardial infarction (STEMI) guidelines recommend pharmaco-invasive treatment if timely primary percutaneous coronary intervention (PCI) is unavailable. Full-dose tenecteplase is associated with an increased risk of intracranial hemorrhage in older patients. Whether pharmaco-invasive treatment with half-dose tenecteplase is effective and safe in older patients with STEMI is unknown.
268. Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial.
作者: Justin A Ezekowitz.;Ciaran J McMullan.;Cynthia M Westerhout.;Ileana L Piña.;Jose Lopez-Sendon.;Kevin J Anstrom.;Adrian F Hernandez.;Carolyn S P Lam.;Christopher M O'Connor.;Burkert Pieske.;Piotr Ponikowski.;Lothar Roessig.;Adriaan A Voors.;Joerg Koglin.;Paul W Armstrong.;Javed Butler.; .
来源: Circ Heart Fail. 2023年16卷9期e010599页
We examined whether the primary composite outcome (cardiovascular death or heart failure hospitalization) was related to differences in background use and dosing of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction enrolled in VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction), a randomized trial of vericiguat versus placebo.
269. Final 3-Year Outcomes of a Randomized Trial Comparing a Self-Expanding to a Balloon-Expandable Transcatheter Aortic Valve.
作者: Jonas Lanz.;Helge Möllmann.;Won-Keun Kim.;Christof Burgdorf.;Axel Linke.;Simon Redwood.;Michael Hilker.;Michael Joner.;Holger Thiele.;Lars Conzelmann.;Lenard Conradi.;Sebastian Kerber.;Christian Thilo.;Stefan Toggweiler.;Bernard Prendergast.;Oliver Husser.;Stefan Stortecky.;Sarah Deckarm.;Arnaud Künzi.;Dik Heg.;Thomas Walther.;Stephan Windecker.;Thomas Pilgrim.; .
来源: Circ Cardiovasc Interv. 2023年16卷7期e012873页
In the SCOPE I trial (Safety and Efficacy of the Symetis ACURATE Neo/TF Compared to the Edwards SAPIEN 3 Bioprosthesis), transcatheter aortic valve implantation with the self-expanding ACURATE neo (NEO) did not meet noninferiority compared with the balloon-expandable SAPIEN 3 (S3) device regarding a composite end point at 30 days due to higher rates of prosthetic valve regurgitation and acute kidney injury. Data on long-term durability of NEO are scarce. Here, we report whether early differences between NEO and S3 translate into differences in clinical outcomes or bioprosthetic valve failure 3 years after transcatheter aortic valve implantation.
270. Inhaled Epoprostenol Compared With Nitric Oxide for Right Ventricular Support After Major Cardiac Surgery.
作者: Kamrouz Ghadimi.;Jhaymie L Cappiello.;Mary Cooter Wright.;Jerrold H Levy.;Benjamin S Bryner.;Adam D DeVore.;Jacob N Schroder.;Chetan B Patel.;Sudarshan Rajagopal.;Svati H Shah.;Carmelo A Milano.; .
来源: Circulation. 2023年148卷17期1316-1329页
Right ventricular failure (RVF) is a leading driver of morbidity and death after major cardiac surgery for advanced heart failure, including orthotopic heart transplantation and left ventricular assist device implantation. Inhaled pulmonary-selective vasodilators, such as inhaled epoprostenol (iEPO) and nitric oxide (iNO), are essential therapeutics for the prevention and medical management of postoperative RVF. However, there is limited evidence from clinical trials to guide agent selection despite the significant cost considerations of iNO therapy.
271. The Effect of Frailty on the Efficacy and Safety of Intensive Blood Pressure Control: A Post Hoc Analysis of the SPRINT Trial.
作者: Zhiyan Wang.;Xin Du.;Chang Hua.;Wenjie Li.;Hao Zhang.;Xinru Liu.;Yufeng Wang.;Chao Jiang.;Jiakun Guo.;Qiang Lv.;Craig S Anderson.;Jianzeng Dong.;Changsheng Ma.
来源: Circulation. 2023年148卷7期565-574页
Frailty is associated with an increased risk of all-cause death and cardiovascular events. However, it is uncertain whether frailty modifies the efficacy and safety of intensive blood pressure control.
272. Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial.
作者: Scott D Solomon.;Charles J Lowenstein.;Ankeet S Bhatt.;Alexander Peikert.;Orly Vardeny.;Mikhail N Kosiborod.;Jeffrey S Berger.;Harmony R Reynolds.;Stephanie Mavromichalis.;Anya Barytol.;Andrew D Althouse.;James F Luther.;Eric S Leifer.;Andrei L Kindzelski.;Mary Cushman.;Michelle N Gong.;Lucy Z Kornblith.;Pooja Khatri.;Keri S Kim.;Lisa Baumann Kreuziger.;Lana Wahid.;Bridget-Anne Kirwan.;Mark W Geraci.;Matthew D Neal.;Judith S Hochman.; .
来源: Circulation. 2023年148卷5期381-390页
COVID-19 has been associated with endothelial injury, resultant microvascular inflammation and thrombosis. Activated endothelial cells release and express P-selectin and von Willebrand factor, both of which are elevated in severe COVID-19 and may be implicated in the disease pathophysiology. We hypothesized that crizanlizumab, a humanized monoclonal antibody to P-selectin, would reduce morbidity and death in patients hospitalized for COVID-19.
273. Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation.
作者: Toru Kondo.;Karola S Jering.;Pardeep S Jhund.;Inder S Anand.;Akshay S Desai.;Carolyn S P Lam.;Aldo P Maggioni.;Felipe A Martinez.;Milton Packer.;Mark C Petrie.;Marc A Pfeffer.;Margaret M Redfield.;Jean L Rouleau.;Dirk J van Veldhuisen.;Faiez Zannad.;Michael R Zile.;Scott D Solomon.;John J V McMurray.
来源: Circ Heart Fail. 2023年16卷7期e010377页
The rate of stroke in patients with heart failure (HF) and preserved ejection fraction but without atrial fibrillation (AF), is uncertain as is whether it is possible to reliably predict the risk of stroke in these patients.
274. Cardiac Magnetic Resonance Imaging Versus Invasive-Based Strategies in Patients With Chest Pain and Detectable to Mildly Elevated Serum Troponin: A Randomized Clinical Trial.
作者: Chadwick D Miller.;Simon A Mahler.;Anna C Snavely.;Subha V Raman.;Jeffrey M Caterino.;Carol L Clark.;Alan E Jones.;Michael E Hall.;Lauren E Koehler.;James F Lovato.;Brian C Hiestand.;Jason P Stopyra.;Carolyn J Park.;Sujethra Vasu.;Michael A Kutcher.;W Gregory Hundley.
来源: Circ Cardiovasc Imaging. 2023年16卷6期e015063页
The optimal diagnostic strategy for patients with chest pain and detectable to mildly elevated serum troponin is not known. The objective was to compare clinical outcomes among an early decision for a noninvasive versus an invasive-based care pathway.
275. Left Atrial Function Predicts Atrial Arrhythmia Recurrence Following Ablation of Long-Standing Persistent Atrial Fibrillation.
作者: Habib Rehman Khan.;Haci Yakup Yakupoglu.;Ines Kralj-Hans.;Shouvik Haldar.;Toufan Bahrami.;Jonathan Clague.;Anthony De Souza.;Wajid Hussain.;Julian Jarman.;David Gareth Jones.;Tushar Salukhe.;Vias Markides.;Dhiraj Gupta.;Rajdeep Khattar.;Tom Wong.; .
来源: Circ Cardiovasc Imaging. 2023年16卷6期e015352页
Left atrial (LA) function following catheter or surgical ablation of de-novo long-standing persistent atrial fibrillation (AF) and its impact on AF recurrence was studied in patients participating in the CASA-AF trial (Catheter Ablation vs. Thoracoscopic Surgical Ablation in Long Standing Persistent Atrial Fibrillation).
276. Prediction of Shock-Refractory Ventricular Fibrillation During Resuscitation of Out-of-Hospital Cardiac Arrest.
作者: Jason Coult.;Betty Y Yang.;Heemun Kwok.;J Nathan Kutz.;Patrick M Boyle.;Jennifer Blackwood.;Thomas D Rea.;Peter J Kudenchuk.
来源: Circulation. 2023年148卷4期327-335页
Out-of-hospital cardiac arrest due to shock-refractory ventricular fibrillation (VF) is associated with relatively poor survival. The ability to predict refractory VF (requiring ≥3 shocks) in advance of repeated shock failure could enable preemptive targeted interventions aimed at improving outcome, such as earlier administration of antiarrhythmics, reconsideration of epinephrine use or dosage, changes in shock delivery strategy, or expedited invasive treatments.
277. Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.
作者: Stephen J Greene.;Eric J Velazquez.;Kevin J Anstrom.;Robert M Clare.;Tracy A DeWald.;Mitchell A Psotka.;Andrew P Ambrosy.;Gerin R Stevens.;John J Rommel.;Tamas Alexy.;Fassil Ketema.;Dong-Yun Kim.;Patrice Desvigne-Nickens.;Bertram Pitt.;Eric L Eisenstein.;Robert J Mentz.; .
来源: Circulation. 2023年148卷2期124-134页
Loop diuretics are a primary therapy for the symptomatic treatment of heart failure (HF), but whether torsemide improves patient symptoms and quality of life better than furosemide remains unknown. As prespecified secondary end points, the TRANSFORM-HF trial (Torsemide Comparison With Furosemide for Management of Heart Failure) compared the effect of torsemide versus furosemide on patient-reported outcomes among patients with HF.
278. Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials.
作者: Michael E Nassif.;Sheryl L Windsor.;Kensey Gosch.;Barry A Borlaug.;Mansoor Husain.;Silvio E Inzucchi.;Dalane W Kitzman.;Darren K McGuire.;Bertram Pitt.;Benjamin M Scirica.;Sanjiv J Shah.;Guillermo Umpierrez.;Bethany A Austin.;Sumant Lamba.;Taiyeb Khumri.;Kavita Sharma.;Mikhail N Kosiborod.
来源: Circ Heart Fail. 2023年16卷7期e009837页
Patients with heart failure (HF) have a high burden of symptoms and physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 (sodium-glucose cotransporter-2) inhibitors on these outcomes vary across the full range of EF remains unclear.
279. Reach Out Emergency Department: A Randomized Factorial Trial to Determine the Optimal Mobile Health Components to Reduce Blood Pressure.
作者: Lesli E Skolarus.;Mackenzie Dinh.;Kelley M Kidwell.;Chun Chieh Lin.;Lorraine R Buis.;Devin L Brown.;Rockefeller Oteng.;Michael Giacalone.;Kimberly Warden.;Deborah E Trimble.;Candace Whitfield.;Zahera Farhan.;Adam Flood.;Dominic Borgialli.;Sacha Montas.;Michael Jaggi.;William J Meurer.
来源: Circ Cardiovasc Qual Outcomes. 2023年16卷5期e009606页
Mobile health (mHealth) strategies initiated in safety-net Emergency Departments may be one approach to address the US hypertension epidemic, but the optimal mHealth components or dose are unknown.
280. Effects of Atrioventricular Optimization on Left Ventricular Reverse Remodeling With Cardiac Resynchronization Therapy: Results of the SMART-CRT Trial.
作者: Michael R Gold.;Kenneth A Ellenbogen.;Christophe Leclercq.;Jonathan Lowy.;Seth J Rials.;Morio Shoda.;Gery Tomassoni.;Ziad Issa.;Jean-Francois Sarrazin.;John M Jennings.;Devi G Nair.;Nicholas Wold.;Patrick Yong.;Michelle M Harbin.;Kenneth M Stein.;Angelo Auricchio.
来源: Circ Arrhythm Electrophysiol. 2023年16卷6期e011714页
The role of atrioventricular optimization (AVO) to improve cardiac resynchronization therapy outcomes remains controversial. Previous post hoc analyses of a multicenter trial showed that measures of electrical dyssynchrony (right ventricular-left ventricular [LV] or LV electrical delay durations) are associated with patients who benefit from AVO.
|